Angiogenesis, Inflammation & Therapeutics | Impact 0.1 (CiteScore) | Online ISSN  2207-872X
RESEARCH ARTICLE   (Open Access)

Ferritin and High Sensitivity C-Reactive Protein (hs-CRP) may predict the COVID-19 patient’s fate

Zahra A. Kheudhier1*, Alaa K. Mossa2

+ Author Affiliations

Journal of Angiotherapy 6(2) 668-676 https://doi.org/10.25163/angiotherapy.625319

Submitted: 06 August 2022  Revised: 27 September 2022  Published: 04 October 2022 

Circulating biomarkers are an essential predictor for the prognosis of COVID-19-infected patients as they represent the severity of inflammation and immune status.

Abstract


Objective: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has rapidly spread worldwide. Clinical outcomes and disease severity are still unknown and can be difficult to predict. In this study, we perform a cross-sectional observational study to investigate the clinical characteristics of ferritin and high sensitivity C-reactive protein status of patients infected with COVID-19 that may predict the COVID-19 patient’s fate. Methods: A total of 106 patients (56 males and 50 females, their ages ranging from 19 to 70 years) who were confirmed to have COVID-19 by real-time RT-PCR were recruited in this study. Blood samples were withdrawn, and biochemical tests (serum ferritin and C-reactive protein) were performed. The gained data were analyzed using GraphPad Prism software. Results: Overall, the findings showed that ferritin and C-reactive protein were increased from day 1 to day 7 and then decreased on day 14 after diagnosis in patients who are released after full recovery. While they still dramatically increased from day 1 to day 7 to day 14 in those who moved to the intensive care unit or died by day 14. No gender-based differences were noted. Conclusions: These findings suggest that the patients fate and disease severity can be predicted at day 7 based on these two biomarkers.

Keywords: COVID-19; COVID-19 patient’s fate; C-reactive protein; ICU; Serum ferritin

References


Ali, N. (2020). Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19. Journal of Medical Virology 92(11), 2409-2411.

Bozkurt, F. T., Tercan, M., Patmano, G., Tanriverdi, T. B., Demir, H. A., & Yurekli, U. F. (2021). Can ferritin levels predict the severity of illness in patients with COVID-19? Cureus, 13(1).

Gagliardi, M. C., Tieri, P., Ortona, E., & Ruggieri, A. (2020). ACE2 expression and sex disparity in COVID-19. Cell Death Discov, 6, 37.

Gómez-Pastora, J., Weigand, M., Kim, J., Wu, X., Strayer, J., Palmer, A. F., Zborowski, M., Yazer, M., & Chalmers, J. J. (2020a). Hyperferritinemia in critically ill COVID-19 patients - Is ferritin the product of inflammation or a pathogenic mediator? Clinica Chimica Acta, 509, 249-251.

Gómez-Pastora, J., Weigand, M., Kim, J., Wu, X., Strayer, J., Palmer, A. F., Zborowski, M., Yazer, M., & Chalmers, J. J. (2020b). Hyperferritinemia in critically ill COVID-19 patients - Is ferritin the product of inflammation or a pathogenic mediator? Clin Chim Acta, 509, 249-251.

Grant, M. C., Geoghegan, L., Arbyn, M., Mohammed, Z., McGuinness, L., Clarke, E. L., & Wade, R. G. (2020). The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries. PLoS One, 15(6), e0234765.

Haitao, T., Vermunt, J. V., Abeykoon, J., Ghamrawi, R., Gunaratne, M., Jayachandran, M., Narang, K., Parashuram, S., Suvakov, S., & Garovic, V. D. (2020). COVID-19 and Sex Differences: Mechanisms and Biomarkers. Mayo Clinic Proceedings, 95(10), 2189-2203.

Huang, I., Pranata, R., Lim, M. A., Oehadian, A., & Alisjahbana, B. (2020a). C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis, 14, 1753466620937175.

Huang, I., Pranata, R., Lim, M. A., Oehadian, A., & Alisjahbana, B. (2020b). C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Therapeutic Advances in Respiratory Disease, 14, 1753466620937175.

Ibekwe, T. S., Fasunla, A. J., & Orimadegun, A. E. (2020). Systematic Review and Meta-analysis of Smell and Taste Disorders in COVID-19. OTO Open, 4(3), 2473974x20957975.

Kopel, J., Perisetti, A., Roghani, A., Aziz, M., Gajendran, M., & Goyal, H. (2020). Racial and Gender-Based Differences in COVID-19. Frontiers in public health, 8, 418-418.

Liu, J., Liu, Y., Xiang, P., Pu, L., Xiong, H., Li, C., Zhang, M., Tan, J., Xu, Y., Song, R., Song, M., Wang, L., Zhang, W., Han, B., Yang, L., Wang, X., Zhou, G., Zhang, T., Li, B., Wang, Y., Chen, Z., & Wang, X. (2020). Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. Journal of Translational Medicine, 18(1), 206.

Luo, H., Liu, S., Wang, Y., Phillips-Howard, P. A., Ju, S., Yang, Y., & Wang, D. (2020). Age differences in clinical features and outcomes in patients with COVID-19, Jiangsu, China: a retrospective, multicentre cohort study. BMJ Open, 10(10), e039887.

Pradhan, A., & Olsson, P.-E. (2020). Sex differences in severity and mortality from COVID-19: are males more vulnerable? Biology of Sex Differences, 11(1), 53.

Salman, J. A.-S., Mahmood, N. N., Abdulsattar, B. O., & Abid, H. A. (2020). The Effectiveness of Probiotics against Viral Infections: A Rapid Review with Focus on SARS-CoV-2 Infection. Open Access Macedonian Journal of Medical Sciences, 8(1), 496-508.

Santesmasses, D., Castro, J. P., Zenin, A. A., Shindyapina, A. V., Gerashchenko, M. V., Zhang, B., Kerepesi, C., Yim, S. H., Fedichev, P. O., & Gladyshev, V. N. (2020). COVID-19 is an emergent disease of aging. Aging Cell, 19(10), e13230.

Singhal, T. (2020). A Review of Coronavirus Disease-2019 (COVID-19). The Indian Journal of Pediatrics, 87(4), 281-286.

Velavan, T. P., & Meyer, C. G. (2020). Mild versus severe COVID-19: Laboratory markers. International Journal of Infectious Diseases, 95, 304-307.

Wang, L. (2020). C-reactive protein levels in the early stage of COVID-19. Médecine et Maladies Infectieuses, 50(4), 332-334.

Yang, A. P., Liu, J. P., Tao, W. Q., & Li, H. M. (2020). The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. International Immunopharmacology, 84, 106504.

Yitbarek, G. Y., Walle Ayehu, G., Asnakew, S., Ayele, F. Y., Bariso Gare, M., Mulu, A. T., Dagnaw, F. T., & Melesie, B. D. (2021). The role of C-reactive protein in predicting the severity of COVID-19 disease: A systematic review. SAGE Open Medicine, 9, 20503121211050755.

Zhang, J. J., Dong, X., Cao, Y. Y., Yuan, Y. D., Yang, Y. B., Yan, Y. Q., Akdis, C. A., & Gao, Y. D. (2020). Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy, 75(7), 1730-1741.

Full Text
Export Citation

View Dimensions


View Plumx



View Altmetric



0
Save
0
Citation
535
View
0
Share